

**PULMONARY FIBROSIS
FOUNDATION**

FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2025 AND 2024

PULMONARY FIBROSIS FOUNDATION

YEARS ENDED JUNE 30, 2025 AND 2024

CONTENTS

	Page
Independent auditors' report	1-2
Financial statements:	
Statements of financial position	3-4
Statements of activities	5-6
Statements of functional expenses	7-8
Statements of cash flows	9-10
Notes to financial statements	11-32



Independent Auditors' Report

Board of Directors
Pulmonary Fibrosis Foundation

Opinion

We have audited the financial statements of Pulmonary Fibrosis Foundation, which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Pulmonary Fibrosis Foundation as of June 30, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Pulmonary Fibrosis Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Pulmonary Fibrosis Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Pulmonary Fibrosis Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Pulmonary Fibrosis Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Ostrow Reisin Berk & Abrams, Ltd.

November 26, 2025

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF FINANCIAL POSITION

June 30,	2025	2024
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 5,956,843	\$ 5,406,039
Investments	7,226,375	7,668,085
Accounts receivable	405,300	131,210
Contributions receivable	14,422	13,073
Contract receivables	630,999	316,264
Prepaid expenses	450,968	243,720
Total current assets	14,684,907	13,778,391
Property and equipment, net	70,151	33,409
Other assets:		
Operating lease right-of-use assets	1,423,030	1,176,724
Investments, noncurrent	1,233,270	69,333
Deposits	15,000	56,631
Intangibles, net	38,631	55,667
Prepaid expenses, noncurrent		150,000
Total other assets	2,709,931	1,508,355
Total assets	\$ 17,464,989	\$ 15,320,155

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF FINANCIAL POSITION (CONTINUED)

June 30,	2025	2024
LIABILITIES AND NET ASSETS		
Current liabilities:		
Accounts payable	\$ 302,292	\$ 194,108
Grants payable	550,716	645,813
Accrued liabilities	154,976	347,227
Contract liabilities	1,278,353	1,475,869
Current portion of operating lease liabilities	6,047	241,446
Total liabilities	2,292,384	2,904,463
Long-term liability:		
Operating lease liabilities, net of current portion	1,458,488	960,978
Total liabilities	3,750,872	3,865,441
Net assets:		
Without donor restrictions	10,204,518	8,436,792
With donor restrictions	3,509,599	3,017,922
Total net assets	13,714,117	11,454,714
Total liabilities and net assets	\$ 17,464,989	\$ 15,320,155

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF ACTIVITIES

Years ended June 30,	2025			2024		
	Without donor restrictions	With donor restrictions	Total	Without donor restrictions	With donor restrictions	Total
Revenue, gains, and other support:						
Public support:						
Contributions	\$ 4,025,678	\$ 362,114	\$ 4,387,792	\$ 2,961,871	\$ 273,001	\$ 3,234,872
Contributed goods and services	428,047		428,047	418,781		418,781
Sponsorships	558,241	1,298,077	1,856,318	586,968	618,280	1,205,248
Special events	1,423,388	356,998	1,780,386	1,248,085	498,485	1,746,570
Total public support	6,435,354	2,017,189	8,452,543	5,215,705	1,389,766	6,605,471
Program service fees:						
Program service fees	1,578,052		1,578,052	2,277,281		2,277,281
Registration	3,650		3,650	340,634		340,634
Total program service fees	1,581,702		1,581,702	2,617,915		2,617,915
Other revenues and support:						
Miscellaneous income	3,866		3,866	5,901		5,901
Net investment income:						
Interest and dividends	625,009		625,009	485,349		485,349
Realized gains on investments	7,485		7,485	3,929		3,929
Unrealized gains on investments	381,542		381,542	452,249		452,249
Investment management fees	(50,348)		(50,348)	(28,702)		(28,702)
Net investment income	963,688		963,688	912,825		912,825

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF ACTIVITIES (CONTINUED)

Years ended June 30,	2025			2024		
	Without donor restrictions	With donor restrictions	Total	Without donor restrictions	With donor restrictions	Total
Total revenue, gains, and other support before net assets released from restrictions	\$ 8,984,610	\$ 2,017,189	\$ 11,001,799	\$ 8,752,346	\$ 1,389,766	\$ 10,142,112
Net assets released from restrictions	1,525,512	(1,525,512)		2,297,521	(2,297,521)	
Total revenue, gains, and other support	10,510,122	491,677	11,001,799	11,049,867	(907,755)	10,142,112
Expenses:						
Program services	5,379,062		5,379,062	7,339,532		7,339,532
Management and general	1,227,090		1,227,090	969,502		969,502
Fundraising	2,107,719		2,107,719	2,087,713		2,087,713
Cost of direct benefits to donors	28,525		28,525	25,900		25,900
Total expenses	8,742,396		8,742,396	10,422,647		10,422,647
Change in net assets	1,767,726	491,677	2,259,403	627,220	(907,755)	(280,535)
Net assets:						
Beginning of year	8,436,792	3,017,922	11,454,714	7,809,572	3,925,677	11,735,249
End of year	\$ 10,204,518	\$ 3,509,599	\$ 13,714,117	\$ 8,436,792	\$ 3,017,922	\$ 11,454,714

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES

Year ended June 30, 2025	Program services										Support services		Cost of direct benefits to donors	
	Education	Legislative Advocacy	Outreach and Awareness	PFF Care Center Network	PFF Registry	PFF Summit	Program Support	Research Grants	Support Groups	Total program services	Management and general	Fundraising		Total
Salaries and wages	\$ 520,837	\$ 69,442	\$ 369,747	\$ 281,687	\$ 404,774	\$ 117,579	\$ 67,403	\$ 71,729	\$ 176,307	\$ 2,079,505	\$ 712,504	\$ 1,217,202		\$ 4,009,211
Employee benefits	47,119	6,333	34,857	28,821	34,772	10,573	6,551	6,411	15,697	191,134	100,966	109,695		401,795
Payroll taxes	37,315	5,022	26,123	20,179	26,229	8,622	5,087	5,042	12,415	146,034	56,424	86,397		288,855
Advertising			5,950	8,145	55		438,974	3		453,127				453,127
Consulting	73,167	38,337	145,029	110,754	682,338	22,972	188,122	13,316	41,625	1,315,660	149,848	23,043		1,488,551
Depreciation and amortization	4,268	267	4,149	1,289	4,674	555	10,224	332	1,144	26,902	2,956	7,964		37,822
Dues and subscriptions	3,210	15,914	2,048	2,456			14,778			38,406	7,764	10,709		56,879
Event expense	15,369		23,922	12,461				6,891	14	58,657	2,858	221,995	\$ 28,525	312,035
Grants	2,500							593,321	24,473	620,294				620,294
Insurance	11,757	951	5,300	4,920	4,730	2,299	1,317	1,178	4,099	36,551	11,514	40,958		89,023
Lease expense	12,675	960	2,836	1,368	982	(1,114)	1,485	1,167	4,058	24,417	5,445	30,754		60,616
Miscellaneous	5,241	428	4,030	5,221	2,073	923	6,120	554	1,852	26,442	21,334	18,007		65,783
Occupancy	7,349	605	3,394	3,085	2,923	1,404	837	747	2,617	22,961	29,635	18,029		70,625
Outside services	23,038		9,890	12,065	49,642	1,750	13,526			109,911	10,058	5,390		125,359
Postage	7,276						1,289			8,565	2,699	35,592		46,856
Printing	6,513					219	7,620			14,352	64	44,541		58,957
Processing fees	2,112	284	1,483	1,137	1,492	481	289	286	703	8,267	16,349	65,064		89,680
Professional fees	7,397	1,856	20,273	3,797	6,156	1,659	980	826	2,826	45,770	36,679	22,237		104,686
Software subscriptions	24,577	1,014	5,584	12,467	5,085	2,397	8,313	14,144	15,349	88,930	12,075	83,339		184,344
Travel	10,346	3,163	20,093	21,420	1,387	1,386	408	2,467	2,507	63,177	47,918	66,803		177,898
Total expenses	\$ 822,066	\$ 144,576	\$ 678,758	\$ 529,077	\$ 1,235,402	\$ 171,760	\$ 773,323	\$ 718,414	\$ 305,686	\$ 5,379,062	\$ 1,227,090	\$ 2,107,719	\$ 28,525	\$ 8,742,396

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF FUNCTIONAL EXPENSES (CONTINUED)

Year ended June 30, 2024	Program services										Support services		Cost of direct benefits to donors	Total
	Education	Legislative Advocacy	Outreach and Awareness	PFF Care Center Network	PFF Registry	PFF Summit	Program Support	Research Grants	Support Groups	Total program services	Management and general	Fundraising		
Salaries and wages	\$ 496,396	\$ 81,197	\$ 464,024	\$ 293,794	\$ 477,728	\$ 181,600	\$ 57,436	\$ 68,916	\$ 213,211	\$ 2,334,302	\$ 679,762	\$ 1,124,050		\$ 4,138,114
Employee benefits	45,480	6,341	39,451	23,867	40,033	11,681	6,147	5,923	19,197	198,120	92,156	100,343		390,619
Payroll taxes	36,186	5,314	32,335	18,801	33,285	9,312	4,846	4,675	15,434	160,188	45,132	81,783		287,103
Advertising			3,967	11,696	5,421	424,844				445,928				445,928
Consulting	71,996	91,106	127,405	109,830	872,174	133,250	169,217	16,909	9,000	1,600,887	20,145	53,613		1,674,645
Depreciation and amortization	6,057	593	9,076	1,401	10,980	564	51,305	420	1,448	81,844	2,343	9,759		93,946
Dues and subscriptions	1,400	15,025	8,964	1,359			6,860			33,608	9,016	435		43,059
Event expense	8,429		21,363	41,541		779,575	4,390	4,119	5,619	865,036	10,558	215,294	\$ 25,900	1,116,788
Grants			(100)					760,000	24,988	784,888				784,888
Insurance	13,192	1,379	6,228	3,224	6,686	2,085	2,856	1,139	3,712	40,501	7,203	37,698		85,402
Lease expense	51,757	6,030	24,722	14,289	27,620	5,830	12,145	4,341	14,876	161,610	23,671	99,244		284,525
Miscellaneous	3,443	310	2,354	2,199	1,354	695	8,865	270	1,571	21,061	10,342	9,677		41,080
Occupancy	10,043	1,170	4,745	2,707	5,395	1,118	2,368	824	2,890	31,260	4,525	19,346		55,131
Outside services	9,982		21,700	12,000	7,500	30,076	14,652	10,997		106,907	9,074	3,809		119,790
Postage	10,365		414		4,985	1,290	2,278			19,332	(5,891)	39,608		53,049
Printing	44,701				5,134	2,745	4,492		358	57,430	1,652	42,680		101,762
Processing fees	1,950	279	1,709	3,840	1,743	505	263	254	825	11,368	4,008	74,540		89,916
Professional fees	9,165	1,023	19,973	2,643	5,189	973	3,076	3,657	2,819	48,518	20,098	30,073		98,689
Software subscriptions	28,136	1,948	8,254	11,308	9,045	1,921	10,965	13,506	12,814	97,897	7,921	79,627		185,445
Travel	7,678		51,323	99,852	6,581	44,858	13,890	6,732	7,933	238,847	27,787	66,134		332,768
Total expenses	\$ 856,356	\$ 211,715	\$ 843,940	\$ 646,622	\$ 1,527,128	\$ 1,213,499	\$ 800,895	\$ 902,682	\$ 336,695	\$ 7,339,532	\$ 969,502	\$ 2,087,713	\$ 25,900	\$ 10,422,647

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF CASH FLOWS

Years ended June 30,	2025	2024
Cash flows from operating activities:		
Change in net assets	\$ 2,259,403	\$ (280,535)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and amortization	37,822	93,946
Amortization of operating lease right-of-use assets	222,524	294,953
Loss on disposal of property and equipment	7,999	
Realized gains on investments	(7,485)	(3,929)
Unrealized gains on investments	(381,542)	(452,249)
Donated securities	(266,316)	(12,347)
Gain on lease termination	(119,575)	
(Increase) decrease in operating assets:		
Accounts receivable	(274,090)	625,099
Contributions receivable	(1,349)	111,405
Contract receivables	(314,735)	(191,514)
Prepaid expenses	(57,248)	432,552
Deposits	41,631	
Increase (decrease) in operating liabilities:		
Accounts payable	108,184	(243,844)
Grants payable	(95,097)	257,126
Accrued liabilities	(192,251)	(683,783)
Contract liabilities	(197,516)	(616,989)
Operating lease liabilities	(87,144)	(248,751)
Net cash provided by (used in) operating activities	683,215	(918,860)
Cash flows from investing activities:		
Proceeds from sales of investments	373,261	39,138
Purchases of investments	(440,145)	(251,382)
Purchases of property and equipment	(65,527)	(2,537)
Purchase of intangibles		(8,766)
Net cash used in investing activities	(132,411)	(223,547)
Net increase (decrease) in cash and cash equivalents	550,804	(1,142,407)
Cash and cash equivalents, beginning of year	5,406,039	6,548,446
Cash and cash equivalents, end of year	\$ 5,956,843	\$ 5,406,039

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

STATEMENTS OF CASH FLOWS (CONTINUED)

Years ended June 30,	2025	2024
Supplemental cash flows information related to leases is as follows:		
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 75,983	\$ 296,755
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	\$ 1,437,201	\$ 26,222
Operating lease right-of-use assets of \$968,370 were terminated along with operating lease liabilities of \$1,012,946 during the year ended June 30, 2025.		

See notes to financial statements.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS

1. Organization and purpose

Nature of activities:

The mission of the Pulmonary Fibrosis Foundation (the Organization) is to mobilize people and resources to provide access to high-quality care and lead research for a cure so that people with pulmonary fibrosis (PF) will live longer, healthier lives. By actively engaging the pulmonary fibrosis community, the Organization has developed essential programs for patients, caregivers, and healthcare professionals across the United States of America to give them a greater understanding of PF and support while living with the disease.

The Organization is primarily funded by contributions, sponsorships, special events, and program service fees.

The programs of the Organization include the following:

Education - The Organization is committed to providing quality disease education to patients, caregivers, family members, and healthcare providers via electronic and printed materials, and webinars. In addition, the PFF Help Center provides resources to the PF community to assist them in their journey to understand the disease.

Legislative Advocacy - The Organization engages policymakers to request increased funding for pulmonary fibrosis research and improved access to oxygen for patients. As part of this advocacy, the Organization hosts a virtual Hill Day event to provide constituents with the opportunity to meet their members of Congress and raise awareness about the impact of Pulmonary Fibrosis and the need for research funding, along with the need to improve access to supplemental oxygen.

Outreach and Awareness - Corporate partnerships seek sponsorships to support the Organization's mission-driven activities from patient-service and educational programs to research initiatives, as well as the biennial PFF Summit. The Organization works with companies to review clinical trial protocols, participate in patient advisory boards, support patient recruitment for clinical trials and market research, and studies evaluating data from the PFF Registry. Additionally, the Organization launched the PFF Corporate Committee, whereby members of the pharmaceutical industry, specialty pharmacy and other key stakeholders meet periodically to discuss the needs of the PF community and create needed improvements. The PFF Ambassador Program empowers patients, caregivers, lung transplant recipients, family members, and those who have lost a loved one to serve as spokespeople for the PF community.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

1. Organization and purpose (continued)

Nature of activities: (continued)

PFF Care Center Network - The PFF Care Center Network (CCN) currently includes 86 individual centers across the country, 80 Care Centers and six Clinical Associates. The Care Center Network provides an opportunity for these expert care teams to work together to improve the quality of care for patients, collaborate in research projects to expedite and broaden scientific discoveries, and work with the PF community to increase awareness and understanding of the disease.

PFF Registry - The goal of the PFF Registry is to establish a comprehensive information source to assist researchers in addressing diagnostic, treatment, and potential cure-related queries and to enable researchers to enhance the quality of care in U.S.-based medical practices. The PFF Registry includes two distinct registries: the PFF Patient Registry which contains physician-reported medical information, biosamples, and high-resolution computed tomography scans, and the PFF Community Registry, which relies on self-reported information submitted by patients, lung transplant recipients, caregivers, and family members. The data collected are anonymized and independently managed by a data coordinating center.

PFF Summit - The PFF Summit is the world's leading conference on pulmonary fibrosis and interstitial lung disease (ILD) held on a biennial basis and draws participants from across the globe.

Program Support - The Marketing Department utilizes the Organization's website, social media content and digital publications to promote events, conferences, and programmatic endeavors of the Organization. In addition, the Organization receives in-kind online advertising from two companies and in-store advertising from a major retailer during Pulmonary Fibrosis Awareness Month (PFAM).

Research Grants - The goal of the multi-year PFF Scholars grants is to support emerging investigators to advance research that could translate into successful therapies, while also enabling these promising researchers to obtain independent funding and continue their innovative research.

Support Groups - The Support Group Leader Network (SGLN) provides a forum for PF support group leaders to connect, exchange ideas, and share best practices. The SGLN consists of over 130 support groups across the country. The Organization also provides phone-based virtual support groups for members of the PF community who either do not have a local support group or are looking for additional support between their other meetings.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies

The significant accounting policies of the Organization are summarized below.

Basis of accounting:

The financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.

Basis of presentation:

Net assets, revenue, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net assets without donor restrictions - Net assets without donor restrictions represent the portion of expendable net assets that are available for operations, which includes net assets designated by the Board for general operating purposes. The Board-designated operating reserves are intended to provide an internal source of funds for situations, such as a sudden increase in expenses, one-time unbudgeted expenses, unanticipated loss in funding, or uninsured losses. The Board-designated operating reserves are to be used and replenished within a reasonably short period of time.

Net assets with donor restrictions - Net assets with donor restrictions represent the portion of net assets that are subject to donor-imposed restrictions related to a time restraint or for a specific use, such as educational materials, outreach and awareness, PFF Care Center Network, PFF Registry, PFF Summit, Program Support, Research Grants, Support Groups, and PFF events. Satisfaction of net assets with donor restrictions (i.e., when the donor-stipulated purpose has been fulfilled, or the stipulated time period has elapsed) is reported as a reclassification from net assets with donor restrictions to net assets without donor restrictions. Some assets with donor restrictions may include a stipulation that assets provided be maintained permanently (perpetual in nature) while permitting the Organization to expend the income generated by the assets in accordance with the provisions of additional donor restrictions and the release of restrictions, respectively. The Organization had no assets that are perpetual in nature as of June 30, 2025 or 2024.

Cash equivalents:

The Organization considers highly liquid investments with maturities of three months or less as cash equivalents.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Investments:

Investments in marketable securities and bonds are reported at fair value based upon market quotations. Donated investments are reflected as contributions at their fair values at date of receipt. The Organization recognized donated investments of \$266,316 and \$12,347 for the years ended June 30, 2025 and 2024, respectively. Realized and unrealized gains and losses less external investment expenses are reflected in the statements of activities as net investment income. Money market accounts that are held in a portfolio at the same institution as other investments are classified as investments. Noncurrent investments include certificates of deposit and bonds that do not mature within the next fiscal year.

Certificates of deposit are carried at amortized cost. Management evaluates the collectibility of investments in certificates of deposit and records an allowance for credit losses representing an estimate of the expected losses that result from all possible default events over the life of the investments. The Organization has assessed the risk of default as less than remote and has not recorded an allowance for credit losses on investments in certificates of deposit as of June 30, 2025 and 2024.

Accounts receivable:

Accounts receivable consist primarily of amounts due from sponsorships for educational programs, PFF Care Center Network, PFF Summit, and PFF events. The Organization recognizes an allowance for credit losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and assessment of specific identifiable accounts considered at risk or uncollectible. There was no allowance for doubtful accounts as of June 30, 2025 and 2024.

Contributions receivable:

Contributions that are mailed by the donor before year-end, but not received until after year-end, are included as contributions receivable. The Organization recognizes an allowance for credit losses on contributions receivable in an amount equal to the estimated probable losses, net of recoveries. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and assessment of specific identifiable accounts considered at risk or uncollectible. There was no allowance for doubtful accounts as of June 30, 2025 and 2024.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Contract receivables:

Contract receivables consist of receivables from contracts with customers and are stated at gross invoice amounts net of provisions for credit losses. Contract receivables are typically outstanding for 30 to 45 days. Management evaluates collectibility on a pooled basis where similar characteristics exist and records an allowance for credit losses in amount equal to the current expected credit losses that results from all possible default events over the expected life of the assets. Contract receivables are evaluated individually when specific customer balances no longer share the risk characteristics and are considered at risk or uncollectible. The allowance is estimated using an analysis of historical loss experience, current receivables aging, and management's assessment of current conditions and reasonable and supportable expectations of future conditions. The Organization writes off receivables when there is information that indicates there is no possibility of recovery. If recoveries are made from accounts previously written off, they will be recognized as an offset to credit loss expense in the year of recovery. There was no allowance for credit losses as of June 30, 2025 and 2024.

Prepaid expenses:

Prepaid expenses consist mainly of prepaid event costs, subscriptions, insurance and postage.

Property and equipment:

Property and equipment are stated at cost, if purchased or fair value at date of donation, if donated. Depreciation is computed using the straight-line method over three to five years for computer hardware and software. The Organization follows the practice of capitalizing all expenditures for property and equipment in excess of \$500. When property and equipment are retired or otherwise disposed of, the costs and related accumulated depreciation are removed from the respective accounts and any gain or loss on disposition is credited or charged to operations. Maintenance and repairs are expensed as incurred.

Asset impairment:

Management reviews the carrying values of property and equipment, intangible assets, and operating lease right-of-use assets for impairment whenever events or circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. When considered impaired, an impairment loss is recognized to the extent the carrying value exceeds the fair value of the asset. There were no indicators of asset impairment during the years ended June 30, 2025 and 2024.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Leases:

The Organization determines whether a contract is a lease at the contract's inception. Identified leases are subsequently measured, classified, and recognized at lease commencement as either a finance lease or an operating lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based on the estimated present value of lease payments to be made over the lease term. The Organization's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Organization will exercise the option.

The lease payments are discounted to present value using a discount rate based on a term commensurate with the lease terms at the lease commencement date. The Organization elected to use a risk-free discount rate for all classes of underlying assets. The portion of payments on operating lease liabilities related to interest, along with the amortization of the related right-of-use assets, is recognized as operating lease cost. Operating lease cost is recognized on a straight-line basis over the lease term and is reported within lease expense on the statements of functional expenses.

Intangibles:

Intangible assets consist of website development and trademark costs. These costs are recognized as an intangible asset and are amortized using the straight-line method over periods between three and ten years.

Grants payable:

Grants payable consists of awards to universities and hospitals for research purposes, which are recognized as expense when they are awarded.

Accrued liabilities:

Accrued liabilities are made up of various expenses, including payroll, medical team-related liabilities, event expenses, and data coordinating center costs that relate to the years ended June 30, 2025 and 2024.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Revenue from contracts with customers:

Revenue streams that meet the definition of an exchange transaction and fall within the scope of Topic 606 are program service fees, registration and special events ticket revenue.

Program service fees

Program service fees are collected to cover costs associated with the delivery of specific programs or services. In general, customers are billed in advance of services provided per the contract terms and payments are typically due upon invoice receipt. The Organization has collaboration agreements with funders which allow them to utilize the PFF Registry data for research studies and grants them access to the PFF Registry data over their contract term and are accounted for as two distinct performance obligations. The transaction price is allocated to the study performance obligation by considering the study type which may utilize raw data, statistical analysis, High Resolution Computed Tomography (HRCT), bio-samples or any combination of the study types. The costs are calculated using time and effort studies from the Organization, the data coordinating center and the cost of raw materials. Access to the PFF Registry data is known as a stand-ready obligation because the data is updated regularly and is readily available to the funder. The difference between the total expected costs and the study costs are the stand-ready costs, which are comprised of material and service costs to collect the PFF Registry data. The amount of unsatisfied performance is recorded to contract liabilities.

Revenue for the PFF Registry stand-ready obligation, which grants customers access to the PFF Registry data along with continual project management by the Organization to maintain the PFF Registry, is recognized over time on a pro-rata monthly amount over the contract term, using an output method based on time elapsed over each month over the life of the contract. The other performance obligation is delivery of certain research studies, which is the delivery of a set of data from the PFF Registry that can be used to complete study projects by the customer. This type of performance obligation is recognized at a point in time when the study data is delivered to the customer.

Other program service fee projects contain separate performance obligations for project management such as the recruitment of patients for surveys or questionnaires or studies, or protocol reviews, teleconferences, participation in advisory boards, or consulting agreements. The project management component of the performance obligation is recognized over time on a pro-rated monthly basis over the contract period. Payments are generally due before the project management is provided.

In addition, the Organization holds a biennial conference, in which registration fees are charged in exchange for conference attendance. Revenue is recognized when the event takes place. Generally speaking, payments are due two months prior to the event.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Revenue from contracts with customers: (continued)

Special events ticket revenue

Special events ticket revenue consists of both a contribution and an exchange transaction. The portion of the ticket price that corresponds to the value of the goods and services received by the attendee is considered an exchange transaction. The purchase of the event ticket is considered a contract between the Organization and the purchaser, as there is a right to enforce the contract for both parties and the Organization expects to collect the full amount it is entitled to, as the tickets are purchased in advance of the event, which typically takes place in March. The Organization provides food and entertainment as part of the ticket price; these are not distinct within the context of the contract and, therefore, represent a single performance obligation. The fee for the ticket represents the transaction price and as there is only one performance obligation, the entire price of the ticket is allocated between the exchange transaction and the contribution component. Consideration is due upon receipt, and the revenue is recognized at a point in time when the event takes place.

Disaggregation of revenue

Below is a comparison of point in time versus over time revenue recognition for the years ended June 30, 2025 and 2024:

Year ended June 30, 2025	Point in time	Over time	Total
Program service fees	\$ 1,301,159	\$ 276,893	\$ 1,578,052
Registration	3,650		3,650
Special events	28,525		28,525
Total	\$ 1,333,334	\$ 276,893	\$ 1,610,227
Year ended June 30, 2024	Point in time	Over time	Total
Program service fees	\$ 898,419	\$ 1,378,862	\$ 2,277,281
Registration	340,634		340,634
Special events	25,900		25,900
Total	\$ 1,264,953	\$ 1,378,862	\$ 2,643,815

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Revenue from contracts with customers: (continued)

Disaggregation of revenue (continued)

The nature, amount, timing, and uncertainty of revenue and cash flows of the Organization are impacted by the concentration of customers in the healthcare industry across the United States of America.

Contract receivables and contract assets

The Organization presents receivables from contracts with customers separately in the statements of financial position. The timing of revenue recognition, billings, and cash collections results in receivables, contract assets, and contract liabilities. Billing may occur subsequent to revenue recognition, resulting in contract assets. Most times, the Organization receives advances or deposits from customers before the revenue is recognized, resulting in contract liabilities. Contract receivables are recorded when the right to the consideration becomes unconditional. Contract receivables were \$630,999, \$316,264 and \$124,750 as of June 30, 2025, 2024 and 2023, respectively. There were no contract assets as of June 30, 2025, 2024 and 2023.

Contract liabilities

The Organization's contract liabilities consist of program service fees and registration fees. The amounts received are recorded as contract liabilities until the Organization satisfies its performance obligations outlined in the agreements. Depending on the nature of the performance obligation, revenue can be recognized on a pro-rata basis over the term of the agreement as the underlying performance obligation is satisfied or be recognized at a point in time when that performance obligation is met. Contract liabilities were \$1,278,353, \$1,475,869 and \$1,776,594 as of June 30, 2025, 2024 and 2023, respectively.

Contributions and sponsorships:

Contributions and sponsorships received are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor restrictions and follows Topic 958. Support that is restricted by the donor is reported as an increase in net assets without donor restrictions if the restriction expires in the same reporting period in which the support is recognized. All other donor-restricted support is reported as an increase in net assets with donor restrictions, depending on the nature of the restriction. When a restriction expires, that is, when a stipulated time restriction ends, or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Contributed goods and services:

Contributed goods and services are reflected as contributions at their fair value at date of donation and are reported as contributions without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. The Organization recognizes the fair value of contributed services received if such services a) create or enhance nonfinancial assets or b) require specialized skills that are provided by individuals possessing those skills and would typically be purchased if not contributed. In addition, the Organization receives services from a large number of volunteers who give significant amounts of their time to the Organization, but these services do not meet the criteria for financial statement recognition. The volunteers are PFF Ambassadors who support the PFF patient community, the PFF Care Center Network affiliates that provide support to patients around the county, the PFF Advocates that are involved in various initiatives like the Supplemental Oxygen Access Reform Act, Support Group leaders, and Team PFF volunteers that host fundraisers in their community to support the Organization and the PFF Walks.

The Organization received approximately \$300,000 of free advertising from a major retailer during each of the years ended June 30, 2025 and 2024. In addition, the Organization received approximately \$128,000 and \$112,000 for on-line advertising from two other companies for the years ended June 30, 2025 and 2024, respectively. The value of the advertising was provided by the donor and valued at estimated fair value using standard industry pricing for similar services. The Organization also received amounts of food and beverages for use at events. The fair value of food and beverages was based on the actual cost of the food and beverages donated as evidenced by invoicing or other support provided by the companies that donated the food and beverages. Contributed goods are not sold and goods and services are only utilized by the Organization. There were no donor restrictions for contributed goods and services recognized during the years ended June 30, 2025 and 2024.

During the years ended June 30, 2025 and 2024, in-kind expenses were allocated as follows:

Year ended June 30, 2025	Program services	Fundraising	Total
Advertising	\$ 427,997		\$ 427,997
Food and beverages		\$ 50	50
Totals	\$ 427,997	\$ 50	\$ 428,047

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Contributed goods and services: (continued)

Year ended June 30, 2024	Program services	Fundraising	Total
Advertising	\$ 412,122		\$ 412,122
Food and beverages		\$ 6,659	6,659
Totals	\$ 412,122	\$ 6,659	\$ 418,781

Advertising:

The Organization expenses advertising costs as they are incurred.

Income taxes:

The Organization is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code (IRC), except for net income derived from unrelated business activities. In addition, the Organization qualifies for the charitable contribution deduction under Section 170(b)(1)(A) and has been classified as an organization other than a private foundation under IRC Section 509(a).

The Organization's income tax filings are subject to audit by various taxing authorities. In evaluating the Organization's activities, management believes its position of tax-exempt status is based on current facts and circumstances, and there have been no uncertain positions taken related to recording income taxes as of June 30, 2025 and 2024.

Functional allocation of expenses:

The costs of providing various programs and activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification detail of expenses by functions. In the statements of functional expenses, the costs that are directly associated with a particular program or supporting service are charged to that functional category, such as travel, consulting, advertising, outside services, processing fees, printing, event expense, professional fees, and grants. Additionally, certain costs have been allocated among the programs and supporting services benefited based on staff time devoted to the functional areas, such as salaries and wages, employee benefits, payroll taxes, depreciation and amortization, dues and subscriptions, insurance, miscellaneous, occupancy, postage, lease expense, and software subscriptions.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

2. Summary of significant accounting policies (continued)

Use of estimates:

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures in the financial statements. Accordingly, actual results could differ from those estimates.

Reclassifications:

Certain amounts in the prior year were reclassified to conform to the current year's presentation on the statements of activities and functional expenses.

Subsequent events:

Subsequent events were evaluated through November 26, 2025, which is the date the financial statements were available to be issued.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

3. Liquidity and availability

The Organization's financial assets available within one year of the statements of financial position date for general expenditures are computed as follows:

June 30,	2025	2024
Total assets at year-end	\$ 17,464,989	\$ 15,320,155
Less nonfinancial assets and noncurrent investments:		
Prepaid expenses	450,968	393,720
Property and equipment, net	70,151	33,409
Operating lease right-of-use assets	1,423,030	1,176,724
Investments, noncurrent	1,233,270	69,333
Deposits	15,000	56,631
Intangibles, net	38,631	55,667
 Total financial assets available within one year	 14,233,939	 13,534,671
Less:		
Assets included above, which are restricted to cover programmatic expenses in the next year:		
Restricted by donors with time or purpose restrictions	3,509,599	3,017,922
 Total financial assets available to management for general expenditures within one year	 \$ 10,724,340	 \$ 10,516,749

The Organization maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities, and other obligations come due. The Organization has been building its liquid assets to ensure the stability of the mission, programs, employment, and ongoing operations of the Organization. Management monitors liquidity by reviewing financial statements and budget-to-actual reports on a monthly basis. As of June 30, 2025 and 2024, management believes that the Organization has a sufficient cash balance, when including the amounts restricted to cover programmatic expenses in the next year, to meet its cash needs for general expenditures within one year. Board-designated net assets are available for operations, as needed, and, therefore, are not included as a reduction to arrive at the total financial assets available to management for general expenditures within one year.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

4. Fair value measurements

FASB ASC 820, *Fair Value Measurement*, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

Level 1	This level consists of quoted prices in active markets for identical investments.
Level 2	This level consists of other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.).
Level 3	This level consists of significant unobservable inputs (including assumptions in determining the fair value of investments).

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. There were no changes in the valuation methodologies during the years ended June 30, 2025 or 2024.

Following is a description of the valuation methodologies uses for assets measured at fair value:

Investments in money market funds, mutual funds, and bonds: Valued at fair value based on quoted market prices.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while management believes that its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

4. Fair value measurements (continued)

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value:

June 30,	2025		2024	
	Level 1	Total	Level 1	Total
Money market funds	\$ 1,346,440	\$ 1,346,440	\$ 1,276,901	\$ 1,276,901
Mutual funds	5,129,635	5,129,635	5,391,764	5,391,764
Bonds	982,765	982,765	69,333	69,333
Total investments at fair value	\$ 7,458,840	7,458,840	\$ 6,737,998	6,737,998
Certificates of deposit		1,000,805		999,420
Total investments		\$ 8,459,645		\$ 7,737,418

Investments as reported on the statements of financial position are comprised as follows:

June 30,	2025			2024		
	Current	Noncurrent	Total	Current	Noncurrent	Total
Money market funds	\$ 1,346,440		\$ 1,346,440	\$ 1,276,901		\$ 1,276,901
Mutual funds	5,129,635		5,129,635	5,391,764		5,391,764
Bonds		\$ 982,765	982,765		\$ 69,333	69,333
Certificates of deposit	750,300	250,505	1,000,805	999,420		999,420
Total investments	\$ 7,226,375	\$ 1,233,270	\$ 8,459,645	\$ 7,668,085	\$ 69,333	\$ 7,737,418

Risks and uncertainties:

The Organization invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the statements of financial position.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

5. Concentrations

The Organization maintains the majority of its cash and cash equivalents at several financial institutions. All deposit accounts at Federal Deposit Insurance Corporation (FDIC)-insured institutions are insured up to \$250,000. As of June 30, 2025 and 2024, cash and cash equivalents in excess of the limits totaled approximately \$1,700,000 and \$1,300,000, respectively. Management believes that the Organization is not exposed to any significant credit risk on cash and cash equivalents.

Investments in certificates of deposit at FDIC-insured institutions are insured up to \$250,000 per institution. The Organization also maintains reserve cash at a brokerage firm. This account is insured by the Securities Investor Protection Corporation up to \$500,000, including a maximum of \$250,000 for claims for cash, and additional coverage is provided by the brokerage firm. As of June 30, 2025 and 2024, certificates of deposit and reserve cash in excess of these limits totaled approximately \$3,500,000 and \$3,300,000, respectively. Management believes that the Organization is not exposed to any credit risk on certificates of deposit and reserve cash.

For the year ended June 30, 2025, one funder accounted for 13% of total public support and program service fees revenue. For the year ended June 30, 2024, two funders accounted for 25% of total public support and program service fees revenue. The Board and management were aware of these concentrations of credit risk when approving the contracts with the funders in prior years in order to provide multi-year funding of the PFF Registry. The Organization is increasing other revenue streams to diversify the funding of the PFF Registry. The Board and management felt that the benefit to research and the patient community outweighed the concentration of credit risk sensitivity in the earlier stages of the project.

Two funders represent 72% and 61% of receivables at June 30, 2025 and 2024, respectively.

6. Related party transactions

Included in contributions on the statements of activities is \$121,346 and \$232,255 from Board members for the years ended June 30, 2025 and 2024, respectively. In addition, the Board raises funds for various PFF Events.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

7. Property and equipment

The Organization's property and equipment were as follows:

June 30,	2025	2024
Computer hardware and software	\$ 205,246	\$ 276,223
Accumulated depreciation	(172,434)	(242,814)
	32,812	33,409
Assets not yet placed into service	37,339	
Property and equipment, net	\$ 70,151	\$ 33,409

Depreciation expense for the years ended June 30, 2025 and 2024 was \$20,786 and \$27,965, respectively.

8. Leases

The Organization leased office and storage facilities with annual escalating lease payments through an operating lease expiring in November 2025. Payments were billed and paid monthly. The lease included one option to renew for three years which the Organization had been reasonably certain to exercise. During July 2024, the landlord (of the office and storage facilities) notified the Organization that it intended to sell the property and that the space would likely be converted to residential property. In April 2025, the landlord formally terminated the lease. Operating lease right-of-use assets of \$968,370 were terminated along with operating lease liabilities of \$1,012,946. In addition, the Organization received \$75,000 in cash resulting in a gain on lease termination of \$119,575.

In March 2025, the Organization moved its operations to a new space and signed a new operating lease expiring in March 2036. Payments are billed and paid monthly and include annual escalations. The lease agreement includes rent abatement for months one through six, months 13 through 15, and months 25 through 27. The lease includes one option to renew for five years which the Organization is not reasonably certain to exercise. The lease also includes an option that the Organization may terminate the lease after eight years, subject to a termination fee.

The Organization also leases copiers through an operating lease expiring in November 2026 and a postage machine through an operating lease expiring in May 2029. Lease payments do not escalate and are billed and paid monthly. There are no variable costs included with these operating leases.

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

8. Leases (continued)

Operating lease cost was \$75,983 and \$299,343 for the years ended June 30, 2025 and 2024, respectively.

Future payments due under the leases are as follows:

Years ending June 30:	Amount
2026	\$ 67,252
2027	137,472
2028	180,464
2029	183,322
2030	181,881
Thereafter	1,109,402
Total undiscounted lease payments	1,859,793
Imputed interest	(395,258)
Total operating lease liabilities	\$ 1,464,535

The following summarizes the weighted-average remaining lease terms and weighted-average discount rates for the operating leases for the years ended June 30, 2025 and 2024:

Years ended June 30,	2025	2024
Weighted-average remaining lease term (years)	10.61	4.37
Weighted-average discount rate	4.14%	3.63%

9. Intangible assets

The Organization's intangible assets were as follows:

June 30,	2025	2024
Trademarks	\$ 69,129	\$ 69,129
Website development and storage	260,786	260,786
	329,915	329,915
Accumulated amortization	(291,284)	(274,248)
Intangible assets, net	\$ 38,631	\$ 55,667

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

9. Intangible assets (continued)

Amortization expense for the years ended June 30, 2025 and 2024 was \$17,036 and \$65,981, respectively.

10. Accrued liabilities

Accrued liabilities consist of the following:

June 30,	2025	2024
Data coordinating center consulting		\$ 214,710
Other accrued expenses	\$ 9,072	12,470
Medical team expenses	70,015	54,597
Payroll and related benefits	75,889	65,450
Total accrued liabilities	\$ 154,976	\$ 347,227

11. Net assets

Without donor restrictions:

Net assets without donor restrictions were as follows:

June 30,	2025	2024
Board-designated operating reserves	\$ 2,909,616	\$ 2,286,096
General	7,294,902	6,150,696
Total	\$ 10,204,518	\$ 8,436,792

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

11. Net assets (continued)

With donor restrictions:

Net assets with donor restrictions were restricted to specific purposes as follows:

June 30,	2025	2024
Education	\$ 356,658	\$ 443,080
Other	112,500	45,250
PFF Care Center Network	319,281	
PFF Registry	782,668	1,031,136
PFF Summit	518,044	
PFF Walks	356,998	498,485
Research Grants	1,010,323	868,845
Support Groups	53,127	131,126
Total	\$ 3,509,599	\$ 3,017,922

The following items were released from net assets with donor restrictions and reclassified to net assets without donor restrictions due to meeting purpose restrictions:

Years ended June 30,	2025	2024
Education	\$ 349,326	\$ 331,127
Other	45,250	45,410
Outreach and Awareness		184,066
PFF Care Center Network		154,655
PFF Registry	249,968	69,114
PFF Summit		441,936
PFF Walks	498,485	310,116
Research Grants	251,357	608,373
Support Groups	131,126	152,724
Total	\$ 1,525,512	\$ 2,297,521

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

12. Commitments

The Organization has entered into agreements with hotels to hold future events. The agreements include penalties if the Organization breaks the contract. No provision has been made in the financial statements for any contingency relating to the commitments. The Organization made the following commitments for a meeting platform and hotel space (includes hotel room cancellation fees) as of June 30, 2025:

<u>June 30, 2025</u>	
March 2026 - Broadway Belts, New York, New York	\$ 7,667
November 2025 - PFF Summit, Chicago, Illinois	624,476
Total	\$ 632,143

In addition, the Organization has several consulting contract commitments as of June 30, 2025 which total \$239,000 through 2026.

13. Special events

Revenues and expenses from special events are shown at gross amounts in the statements of activities. Gross revenue for each event was as follows:

Year ended June 30, 2025	Without donor restrictions	With donor restrictions	Total revenue
Event			
PFF Walk fiscal year 2024-2025	\$ 856,668		\$ 856,668
PFF Walk fiscal year 2025-2026		\$ 356,998	356,998
Broadway Belts!	566,720		566,720
Total	\$ 1,423,388	\$ 356,998	\$ 1,780,386

PULMONARY FIBROSIS FOUNDATION

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

13. Special events (continued)

Year ended June 30, 2024			
Event	Without donor restrictions	With donor restrictions	Total revenue
PFF Walk fiscal year 2023-2024	\$ 738,184		\$ 738,184
PFF Walk fiscal year 2024-2025		\$ 498,485	498,485
Broadway Belts!	509,901		509,901
Total	\$ 1,248,085	\$ 498,485	\$ 1,746,570

The PFF Walk Program was comprised of PFF Walks in the following cities: Chicago, New York City, the District of Columbia, Dallas, San Francisco, and Pittsburgh. Net assets with donor restrictions for the fiscal year 2025 PFF Walk of \$498,485 were reflected on the fiscal year 2024 financial statements as net assets with donor restrictions and released in fiscal year 2025. Net assets with donor restrictions for the fiscal year 2024 PFF Walk of \$310,116 were reflected on the fiscal year 2023 financial statements as net assets with donor restrictions and released in fiscal year 2024. Restrictions on these funds are related to timing of the event or receipt of the funds.

During the years ended June 30, 2025 and 2024, the Organization also had third parties hold special events in honor of the Organization. The net proceeds of each event are remitted by the third parties to the Organization after the event has been completed. These proceeds are recorded as contributions, as the events are not held by the Organization.

14. Retirement plan

The Organization provides a 401(k) salary reduction plan that covers all full-time employees and part-time employees who work 1,000 hours in a single year. Contributions are made by the employees at an amount or percentage of their salary not to exceed applicable Internal Revenue Service limits. The Organization contributes 3% of the employee's base salary into the plan, irrespective of the employee's level of deferral. The Organization made employer contributions to the plan of \$113,412 and \$113,906 for the years ended June 30, 2025 and 2024, respectively.